Operating Income (Loss) of VERTEX PHARMACEUTICALS INC / MA from 31 Mar 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
VERTEX PHARMACEUTICALS INC / MA quarterly and annual Operating Income (Loss) in USD history and change rate from 31 Mar 2010 to 31 Dec 2025.
  • VERTEX PHARMACEUTICALS INC / MA Operating Income (Loss) for the quarter ending 31 Dec 2025 was $1,205,900,000, a 18% increase year-over-year.
  • VERTEX PHARMACEUTICALS INC / MA Operating Income (Loss) for the twelve months ending 31 Dec 2025 was $4,173,300,000.
  • VERTEX PHARMACEUTICALS INC / MA annual Operating Income (Loss) for 2025 was $4,173,300,000.
  • VERTEX PHARMACEUTICALS INC / MA annual Operating Income (Loss) for 2024 was $232,900,000, a 106% decline from 2023.
  • VERTEX PHARMACEUTICALS INC / MA annual Operating Income (Loss) for 2023 was $3,832,000,000, a 11% decline from 2022.
Source SEC data
View on sec.gov
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

VERTEX PHARMACEUTICALS INC / MA Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $4,173,300,000 $1,205,900,000 +$179,900,000 +18% 01 Oct 2025 31 Dec 2025 10-K 13 Feb 2026 2025 FY
Q3 2025 $3,993,400,000 $1,186,200,000 +$69,900,000 +6.3% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $3,923,500,000 $1,151,100,000 +$4,665,800,000 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $742,300,000 $630,100,000 -$509,400,000 -45% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $232,900,000 $1,026,000,000 +$37,500,000 +3.8% 01 Oct 2024 31 Dec 2024 10-K 13 Feb 2026 2025 FY
Q3 2024 $270,400,000 $1,116,300,000 +$78,200,000 +7.5% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $348,600,000 $3,514,700,000 -$4,541,100,000 -442% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $4,192,500,000 $1,139,500,000 +$360,500,000 +46% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $3,832,000,000 $988,500,000 -$45,000,000 -4.4% 01 Oct 2023 31 Dec 2023 10-K 13 Feb 2026 2025 FY
Q3 2023 $3,877,000,000 $1,038,100,000 -$88,600,000 -7.9% 01 Jul 2023 30 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 $3,965,600,000 $1,026,400,000 -$79,900,000 -7.2% 01 Apr 2023 30 Jun 2023 10-Q 02 Aug 2024 2024 Q2
Q1 2023 $4,045,500,000 $779,000,000 -$261,900,000 -25% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $4,307,400,000 $1,033,500,000 +$155,800,000 +18% 01 Oct 2022 31 Dec 2022 10-K 13 Feb 2025 2024 FY
Q3 2022 $4,151,600,000 $1,126,700,000 +$72,200,000 +6.8% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $4,079,400,000 $1,106,300,000 +$1,144,200,000 01 Apr 2022 30 Jun 2022 10-Q 02 Aug 2023 2023 Q2
Q1 2022 $2,935,200,000 $1,040,900,000 +$153,100,000 +17% 01 Jan 2022 31 Mar 2022 10-Q 02 May 2023 2023 Q1
Q4 2021 $2,782,100,000 $877,700,000 +$131,908,000 +18% 01 Oct 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
Q3 2021 $2,650,192,000 $1,054,500,000 +$382,259,000 +57% 01 Jul 2021 30 Sep 2021 10-Q 28 Oct 2022 2022 Q3
Q2 2021 $2,267,933,000 $37,900,000 -$755,933,000 -105% 01 Apr 2021 30 Jun 2021 10-Q 05 Aug 2022 2022 Q2
Q1 2021 $3,023,866,000 $887,800,000 +$167,576,000 +23% 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022 2022 Q1
Q4 2020 $2,856,290,000 $745,792,000 +$194,327,000 +35% 01 Oct 2020 31 Dec 2020 10-K 11 Feb 2021 2020 FY
Q3 2020 $2,661,963,000 $672,241,000 +$572,908,000 +577% 01 Jul 2020 30 Sep 2020 10-Q 03 Nov 2021 2021 Q3
Q2 2020 $2,089,055,000 $718,033,000 +$448,073,000 +166% 01 Apr 2020 30 Jun 2020 10-Q 30 Jul 2021 2021 Q2
Q1 2020 $1,640,982,000 $720,224,000 +$443,416,000 +160% 01 Jan 2020 31 Mar 2020 10-Q 30 Apr 2021 2021 Q1
Q4 2019 $1,197,566,000 $551,465,000 +$423,743,000 +332% 01 Oct 2019 31 Dec 2019 10-K 11 Feb 2021 2020 FY
Q3 2019 $773,823,000 $99,333,000 -$106,316,000 -52% 01 Jul 2019 30 Sep 2019 10-K 11 Feb 2021 2020 FY
Q2 2019 $880,139,000 $269,960,000 +$97,082,000 +56% 01 Apr 2019 30 Jun 2019 10-K 11 Feb 2021 2020 FY
Q1 2019 $783,057,000 $276,808,000 +$147,907,000 +115% 01 Jan 2019 31 Mar 2019 10-K 11 Feb 2021 2020 FY
Q4 2018 $635,150,000 $127,722,000 +$1,985,000 +1.6% 01 Oct 2018 31 Dec 2018 10-K 13 Feb 2020 2019 FY
Q3 2018 $633,165,000 $205,649,000 +$531,692,000 01 Jul 2018 30 Sep 2018 10-K 13 Feb 2020 2019 FY
Q2 2018 $101,473,000 $172,878,000 +$120,171,000 +228% 01 Apr 2018 30 Jun 2018 10-K 13 Feb 2020 2019 FY
Q1 2018 $18,698,000 $128,901,000 -$141,941,000 -52% 01 Jan 2018 31 Mar 2018 10-K 13 Feb 2020 2019 FY
Q4 2017 $123,243,000 $125,737,000 +$86,097,000 +217% 01 Oct 2017 31 Dec 2017 10-K 13 Feb 2019 2018 FY
Q3 2017 $37,146,000 $326,043,000 -$307,316,000 -1641% 01 Jul 2017 30 Sep 2017 10-K 13 Feb 2019 2018 FY
Q2 2017 $344,462,000 $52,707,000 +$49,354,000 +1472% 01 Apr 2017 30 Jun 2017 10-K 13 Feb 2019 2018 FY
Q1 2017 $295,108,000 $270,842,000 +$285,172,000 01 Jan 2017 31 Mar 2017 10-K 13 Feb 2019 2018 FY
Q4 2016 $9,936,000 $39,640,000 +$93,344,000 01 Oct 2016 31 Dec 2016 10-K 15 Feb 2018 2017 FY
Q3 2016 $83,408,000 $18,727,000 +$51,299,000 +73% 01 Jul 2016 30 Sep 2016 10-K 15 Feb 2018 2017 FY
Q2 2016 $134,707,000 $3,353,000 +$174,517,000 01 Apr 2016 30 Jun 2016 10-K 15 Feb 2018 2017 FY
Q1 2016 $309,224,000 $14,330,000 +$157,655,000 +92% 01 Jan 2016 31 Mar 2016 10-K 15 Feb 2018 2017 FY
Q4 2015 $466,879,000 $53,704,000 +$99,921,000 +65% 01 Oct 2015 31 Dec 2015 10-K 23 Feb 2017 2016 FY
Q3 2015 $566,800,000 $70,026,000 +$72,177,000 +51% 01 Jul 2015 30 Sep 2015 10-K 23 Feb 2017 2016 FY
Q2 2015 $638,977,000 $171,164,000 +$9,378,000 +5.2% 01 Apr 2015 30 Jun 2015 10-K 23 Feb 2017 2016 FY
Q1 2015 $648,355,000 $171,985,000 +$44,057,000 +20% 01 Jan 2015 31 Mar 2015 10-K 23 Feb 2017 2016 FY
Q4 2014 $692,412,000 $153,625,000 -$143,344,000 -1394% 01 Oct 2014 31 Dec 2014 10-K 16 Feb 2016 2015 FY
Q3 2014 $549,068,000 $142,203,000 -$18,647,000 -15% 01 Jul 2014 30 Sep 2014 10-K 16 Feb 2016 2015 FY
Q2 2014 $530,421,000 $180,542,000 -$133,510,000 -284% 01 Apr 2014 30 Jun 2014 10-K 16 Feb 2016 2015 FY
Q1 2014 $396,911,000 $216,042,000 +$213,097,000 +50% 01 Jan 2014 31 Mar 2014 10-K 16 Feb 2016 2015 FY
Q4 2013 $610,008,000 $10,281,000 +$67,195,000 +87% 01 Oct 2013 31 Dec 2013 10-K 13 Feb 2015 2014 FY
Q3 2013 $677,203,000 $123,556,000 -$122,485,000 -11437% 01 Jul 2013 30 Sep 2013 10-K 13 Feb 2015 2014 FY
Q2 2013 $554,718,000 $47,032,000 -$36,262,000 -337% 01 Apr 2013 30 Jun 2013 10-K 13 Feb 2015 2014 FY
Q1 2013 $518,456,000 $429,139,000 -$520,788,000 -568% 01 Jan 2013 31 Mar 2013 10-K 13 Feb 2015 2014 FY
Q4 2012 $2,332,000 $77,476,000 -$301,378,000 -135% 01 Oct 2012 31 Dec 2012 10-K 11 Feb 2014 2013 FY
Q3 2012 $303,710,000 $1,071,000 -$216,778,000 -100% 01 Jul 2012 30 Sep 2012 10-K 11 Feb 2014 2013 FY
Q2 2012 $520,488,000 $10,770,000 +$155,120,000 +94% 01 Apr 2012 30 Jun 2012 10-K 11 Feb 2014 2013 FY
Q1 2012 $365,368,000 $91,649,000 +$251,548,000 01 Jan 2012 31 Mar 2012 10-K 11 Feb 2014 2013 FY
Q4 2011 $113,820,000 $223,902,000 +$390,536,000 01 Oct 2011 31 Dec 2011 10-K 01 Mar 2013 2012 FY
Q3 2011 $276,716,000 $215,707,000 +$415,295,000 01 Jul 2011 30 Sep 2011 10-K 01 Mar 2013 2012 FY
Q2 2011 $692,011,000 $165,890,000 +$3,683,000 +2.2% 01 Apr 2011 30 Jun 2011 10-K 01 Mar 2013 2012 FY
Q1 2011 $695,694,000 $159,899,000 +$383,000 +0.24% 01 Jan 2011 31 Mar 2011 10-K 01 Mar 2013 2012 FY
Q4 2010 $696,077,000 $166,634,000 01 Oct 2010 31 Dec 2010 10-K 22 Feb 2012 2011 FY
Q3 2010 $199,588,000 01 Jul 2010 30 Sep 2010 10-K 22 Feb 2012 2011 FY
Q2 2010 $169,573,000 01 Apr 2010 30 Jun 2010 10-K 22 Feb 2012 2011 FY
Q1 2010 $160,282,000 01 Jan 2010 31 Mar 2010 10-K 22 Feb 2012 2011 FY

VERTEX PHARMACEUTICALS INC / MA Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $4,173,300,000 +$4,406,200,000 01 Jan 2025 31 Dec 2025 10-K 13 Feb 2026 2025 FY
2024 $232,900,000 -$4,064,900,000 -106% 01 Jan 2024 31 Dec 2024 10-K 13 Feb 2026 2025 FY
2023 $3,832,000,000 -$475,400,000 -11% 01 Jan 2023 31 Dec 2023 10-K 13 Feb 2026 2025 FY
2022 $4,307,400,000 +$1,525,300,000 +55% 01 Jan 2022 31 Dec 2022 10-K 13 Feb 2025 2024 FY
2021 $2,782,100,000 -$74,200,000 -2.6% 01 Jan 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
2020 $2,856,300,000 +$1,658,800,000 +139% 01 Jan 2020 31 Dec 2020 10-K 10 Feb 2023 2022 FY
2019 $1,197,500,000 +$562,350,000 +89% 01 Jan 2019 31 Dec 2019 10-K 09 Feb 2022 2021 FY
2018 $635,150,000 +$511,907,000 +415% 01 Jan 2018 31 Dec 2018 10-K 11 Feb 2021 2020 FY
2017 $123,243,000 +$113,307,000 +1140% 01 Jan 2017 31 Dec 2017 10-K 13 Feb 2020 2019 FY
2016 $9,936,000 +$476,815,000 01 Jan 2016 31 Dec 2016 10-K 13 Feb 2019 2018 FY
2015 $466,879,000 +$225,533,000 +33% 01 Jan 2015 31 Dec 2015 10-K 15 Feb 2018 2017 FY
2014 $692,412,000 -$82,404,000 -14% 01 Jan 2014 31 Dec 2014 10-K 23 Feb 2017 2016 FY
2013 $610,008,000 -$656,735,000 -1405% 01 Jan 2013 31 Dec 2013 10-K 16 Feb 2016 2015 FY
2012 $46,727,000 -$67,093,000 -59% 01 Jan 2012 31 Dec 2012 10-K 13 Feb 2015 2014 FY
2011 $113,820,000 +$809,897,000 01 Jan 2011 31 Dec 2011 10-K 11 Feb 2014 2013 FY
2010 $696,077,000 01 Jan 2010 31 Dec 2010 10-K 01 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.